| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b0415d6923e2f80c6c8872becb568967 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-289
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1096
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K101-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-87 |
| filingDate |
2018-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e6621c11d36b002648f9321fcac0a94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53ed0c755c318c342b8ef5341ec8eb0f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb94bea246ba616d1d31b15ea11985ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2df060e9e9c6319480bd1d298d7d4b7 |
| publicationDate |
2019-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019084258-A1 |
| titleOfInvention |
METHODS OF CONDITIONING BASED ON ANTI-CD45 AND USES THEREOF IN COMBINATION WITH GENETICALLY MODIFIED CELL THERAPIES |
| abstract |
The present invention relates to a method of depleting hematopoietic stem cells of a subject comprising administering to an effective amount of a radiolabelled anti-CD45 antibody, such as 131 I-BC8 or 225 Ac-BC8. The present invention also relates to a method of treating a subject having a non-cancerous disorder that can be treated via a genetically modified cell-based therapy comprising (i) administering about a a radiolabeled anti-CD45 antibody effective in depleting the subject's hematopoietic stem cells, and (ii) after a suitable period of time, implementing a therapy on the subject to treat the disorder of the subject. Finally, the present invention relates to articles of manufacture for carrying out the methods of the invention. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023118608-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3958905-A4 |
| priorityDate |
2017-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |